UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

For the Month of January 2026

Commission File Number: 001-42810

YD Bio Limited

12F., No. 3, Xingnan St.,

Nangang Dist.,

Taipei City 115001, Taiwan

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒     Form 40-F ☐

~~Appointment~~Entry Into a Letter of ~~Certain~~Intent ~~Directors~~ to Acquire Safe Save Medical Cell Sciences & Technology Co., Ltd.

On January 1620, 2026, ~~the~~YD ~~Board~~Bio ~~of Directors~~ Limited (the “~~Board~~Company”) of YDentered ~~Bio~~into ~~Limited~~a binding letter of intent (the “~~Company~~LOI”) ~~approved~~with ~~the~~Safe ~~appointment~~Save ofMedical DrCell Sciences & Technology Co., ~~Chang~~Ltd. as(“SSMC”, ~~Chairman~~together ofwith the ~~Compensation~~Company, ~~Committee~~the ~~and~~“Parties”), aspursuant ~~a member~~to ofwhich the Company’s ~~Audit~~intends to ~~Committee~~acquire, ~~and~~indirectly ~~Nominating~~through ~~and~~an ~~Corporate~~offshore ~~Governance~~holding ~~Committee,~~company ~~effective~~to ~~immediately.~~be ~~Additionally~~formed, on ~~January~~all ~~16,~~of ~~2026,~~ the ~~Board~~shares, ~~approved~~assets ~~the~~and ~~appointment~~business of DrSSMC (the “Transaction”). Under Luthe asLOI, ~~Chairman~~SSMC ofwill ~~the~~undertake ~~Nominating~~a ~~and~~corporate ~~Corporate~~restructuring ~~Governance~~to ~~Committee and~~establish asSafe aSave ~~member~~Cell of(KY) Holdings Limited (the “KY Company”), which will hold 100% of SSMC’s ~~Audit~~equity, ~~Committee~~ and ~~Compensation~~the ~~Committee,~~Company ~~effective~~intends ~~immediately~~to acquire 100% of the equity interests of the KY Company.

~~Dr.~~The ~~Chang~~total ~~and~~consideration ~~Dr.~~for Luthe Transaction ~~have~~is noexpected ~~direct~~to orbe ~~indirect~~NT$839,832,000, ~~material~~and ~~interest~~be ~~in any~~comprised ~~transaction~~of ~~required~~a tomix beof ~~disclosed~~cash ~~pursuant~~and toordinary ~~Item~~shares ~~404(a)~~ of ~~Regulation~~the ~~S-K~~Company, ~~and~~par ~~have~~value no$0.0001 (the ~~arrangement~~“Ordinary orShares”), ~~understanding~~ with ~~any other~~specific ~~person~~shareholders ~~required~~of toSSMC beholding ~~disclosed~~more ~~pursuant~~than to10% ~~Item 401~~(a)including ofSSMC’s ~~Regulation~~founder ~~S-K.~~and ~~Dr.~~affiliates) to ~~Chang~~receive ~~and~~Ordinary ~~Dr.~~Shares Luvia ~~have~~share noswap, ~~family~~and ~~relationships~~other ~~required to~~shareholders be(the ~~disclosed~~“general ~~pursuant~~shareholders”) tohaving ~~Item~~the ~~401(d)~~option ofto ~~Regulation~~receive cash ~~S-K~~or Ordinary Shares.

~~Additionally,~~Ordinary onShares ~~January~~issued ~~20,~~as ~~2026,~~consideration will ~~the~~be ~~Company~~subject ~~notified~~to ~~Nasdaq that~~transfer ~~the~~restrictions ~~Company~~in ~~has~~accordance ~~regained compliance~~ with ~~the~~applicable ~~requirements~~U.S. ~~for~~securities ~~the~~laws, ~~Audit~~including ~~Committee~~a ~~pursuant~~six-month tolock-up ~~Nasdaq~~for ~~Listing~~general shareholders ~~Rule 5605,~~ and ~~that the~~a ~~Company~~one-year islock-up nofor ~~longer~~specific ~~subject to the cure period under Nasdaq Listing Rule 5605(c)(4)(B)~~shareholders.

Completion of the Transaction is subject to customary closing conditions, including completion of the Company’s due diligence, completion of SSMC’s restructuring, and the absence of any material adverse change in SSMC’s business, assets, or financial condition. The Parties target completion of due diligence by March 20, 2026, and expect to close within 30 days thereafter, subject to satisfaction of all conditions precedent. Upon closing, the KY Company is expected to become a wholly owned subsidiary of the Company, resulting in the Company’s indirect ownership and control of all of SSMC’s shares, business, and assets.

There can be no assurance that the Parties will enter into definitive agreements or that the Transaction will be completed within the anticipated timeframe or on the terms contemplated by the LOI. The terms of the LOI is expected to be superseded by a definitive agreement.

Issuance of Press Release

On January 29, 2026, the Company issued a press release announcing its entry into the LOI, which is attached as Exhibit 99.1 to this Report on Form 6-K (this “Report”).

The information contained in this Report (other than Exhibit 99.1) is hereby incorporated by reference into the Company’s Registration Statement on Form S-8 (File No. 333-292554) to be a part thereof, to the extent not superseded by documents or reports subsequently filed or furnished. This Report, including Exhibit 99.1, shall not otherwise be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as expressly set forth by specific reference in such filing.

Forward Looking Statements

Matters discussed in this report may constitute forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical facts. The words “believe”, “may”, “intends”, “expect”, “pending” and similar expressions identify forward-looking statements. The forward-looking statements in this report are based upon various assumptions. Although we believe that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond our control, we cannot assure you that we will achieve or accomplish these expectations. Except as required by law, the Company disclaims any duty to update these forward-looking statements.

EXHIBIT INDEX

The following exhibits are being filed herewith:

Exhibit No.		Description
99.1		Press Release, dated January 29, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

January 21 30, 2026

	YD BIO LIMITED

	By:	/s/ Edmund Hen
	Name:	Edmund Hen
	Title:	Chief Financial Officer

Filing Compare · YD Bio Ltd